Valproate original pack safety — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Maintain risk materials and follow valproate original-pack supply requirements
Valproate has major teratogenic and neurodevelopmental risks and is subject to risk minimisation requirements. Patients must receive appropriate warnings, patient information and cards, and original-pack supply rules should be followed unless a documented clinical reason applies. Previous use does not remove the need for counselling. Omitting warnings undermines informed, safe use.
Reference: MHRA Valproate guidance; BNF